Announcement for those with advanced breast cancer (metastatic breast cancer)
You may qualify for a clinical trial for a potential new treatment.
What is it?
- A randomized phase III trial of endocrine therapy plus entinostat or placebo in patients with hormone receptor-positive advanced breast cancer.
Who can participate?
- Trial is open to pre-, and post menopausal women and all men with hormone receptor-positive breast cancer that cannot be removed by surgery (locally advanced) or has spread (metastasized) to another part of the body.
- Patients will not be eligible if they are HER2-positive.
Learn more about who qualifies and find trial locations by visiting www.BreastCancerStudyE2112.com
Note: More details re. ELIGIBILITY OF STUDY E2112
- It is open to pre-, peri-, and postmenopausal women and all men with:
- hormone receptor– positive and/or progesterone receptor–positive breast cancer
- that cannot be removed by surgery (locally advanced) or has spread (metastasized) to another part of the body.
- Patients will not be eligible if they are HER2 (human epidermal growth factor receptor-2)-positive.
- Individuals who participate must have recovered from side effects of past therapies.
- Hormone receptor-positive cancers may be more likely to respond to hormone therapies, such as exemestane.
- Patients must have completed prior endocrine therapy at least two weeks before being assigned a study group; an exception is
exemestane, which is allowed in patients with metastatic disease if they started exemestane within four weeks of being assigned to a study group.
- Patients who received everolimus, prior palbociclib, or other cyclin-dependent kinase (CDK) inhibitor (
ribociclib, abemaciclib) and prior fulvestrant use are allowed and may participate as long as the drug was completed two weeks before being assigned a study group.
- Patients may not participate if they have been treated with entinostat, valproic acid (Depakote®, Epilim®, Valparin, Vilapro, Stavzor®), or vorinostat (Zolinza®).
See more detailed inclusion and exclusion criteria at clinicaltrials.gov